Rajan Bajracharya

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Joseph F. Merola, Robert Landewé, Iain B. McInnes et al. · The Lancet · 2022 · 158 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

Iain B. McInnes, Akihiko Asahina, Laura C. Coates et al. · The Lancet · 2022 · 157 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

Christopher T. Ritchlin, Laura C. Coates, Iain B. McInnes et al. · Annals of the Rheumatic Diseases · 2023 · 43 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: <scp>Three‐Year</scp> Results From a Phase <scp>IIb</scp> Randomized Controlled Trial and Its <scp>Open‐Label</scp> Extension Study

Laura C. Coates, Iain B. McInnes, Joseph F. Merola et al. · Arthritis & Rheumatology · 2022 · 37 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Laura C. Coates, Robert Landewé, Iain B. McInnes et al. · RMD Open · 2024 · 36 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14